User: Violet: Healthcare: slopechart_SLNO.jpg

SLNO - From TheBearCave, Scorpion Capital called the company a “rare-disease price-gouging scheme” built on “suspect data and sham clinical trials.” Scorpion alleged its flagship drug, VYKAT XR, “may be at risk of being withdrawn from market” due to reports of causing heart failure in children.  
Target of gap at 50.25 does not look unreasonable.